Judge ends EmblemHealth’s Soliris patent-related antitrust class action against Alexion, citing favorable Samsung Bioepis settlement

Context: EmblemHealth, Inc., a health insurer, filed a putative class action in April 2025 (see below) accusing Alexion, an AstraZeneca company, of overcharging for its rare disease drug Soliris. EmblemHealth alleged that Alexion enforced five fraudulently obtained patents to keep biosimilars off the U.S. market from at least March 2022 until Amgen and Samsung Bioepis launched in March and April 2025. On December 19, 2025, Judge Brian E. Murphy of the United States District Court for the District of Massachusetts dismissed the claims to the extent they relied on that fraud theory, because an indirect purchaser like EmblemHealth lacks antitrust standing for it. He let the claims go forward that relied on the second exception to antitrust immunity for patent enforcement, namely that Alexion’s January 2024 patent suit against Samsung Bioepis was a sham.

To Read The Full Story

Continue reading your article with a Membership

Court and counsel

United States District Court for the District of Massachusetts: Judge Brian E. Murphy

EmblemHealth is being represented by Radice Law Firm’s April D. Lambert, Kenneth Pickle, and John D. Radice; Hagens Berman Sobol Shapiro’s Thomas M. Sobol, Chris O’Brien, Daniel Polonsky, Gregory T. Arnold, Hannah W. Brennan, and Kristen Anne Johnson; and Rawlings and Associates’ Mark D. Fischer.

Meanwhile Alexion is being represented by Covington & Burling’s Timothy C. Hester and Ashley E. Bass, together with Foley Hoag’s Howard Weiss and Kenneth S. Leonetti.